IL10 and neoplasm: Furthermore, interleukin 10 (IL‐10), which is secreted by M2‐type TAMs and acts as an anti‐inflammatory factor, was reduced fourfold compared with that in the control group (Figure S25, Supporting Information), and IL‐12, which is secreted by M1‐type TAMs and acts as a proinflammatory factor,[35] was increased by 6.7‐fold (Figure S25, Supporting Information), demonstrating that the combined treatment promoted the conversion of tumor‐promoting M2‐type TAMs to tumor‐inhibiting M1‐type TAMs.